Category: Targeted Therapy
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in patients with advanced solid tumors that have a KRAS G12C mutation.
Study Name This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 (adagrasib) in…
ICP-CL-00303
Study Name ICP-CL-00303 ClinicalTrials.gov Identifier (if applicable) NCT04565275 Clinical Trial Category (check all that apply) Beyond First Line Therapy Targeted…
Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC)
Study Name Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS…
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors
Study Name Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors ClinicalTrials.gov Identifier (if applicable) NCT04056910 Clinical Trial Category (check all…
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210)
Study Name CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the…
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Study Name CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT04660929 Clinical Trial Category (check…
A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients with Advanced Biliary Tract Cancer (BTC)
Study Name A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in ClinicalTrials.gov Identifier (if applicable)…
PROOF Trial: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Study Name PROOF Trial: Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations…
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Study Name Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene ClinicalTrials.gov Identifier…
Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3
Study Name Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors Phase II, multi-center, open-label study of patients…
Safety and Tolerability of TNG462 in Patients with MTAP-deleted Solid Tumors
Study Name Safety and Tolerability of TNG462 in Patients with MTAP-deleted Solid Tumors ClinicalTrials.gov Identifier (if applicable) NCT05732831 Clinical Trial Category (check…